Inhibrx (Inhibrx) 3-Year Revenue Growth Rate : -57.80% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inhibrx 3-Year Revenue Growth Rate?

Inhibrx's Revenue per Share for the three months ended in Mar. 2024 was $0.00.

During the past 12 months, Inhibrx's average Revenue per Share Growth Rate was 9.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -57.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was -37.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 7 years, the highest 3-Year average Revenue per Share Growth Rate of Inhibrx was 22.50% per year. The lowest was -57.80% per year. And the median was -28.40% per year.

Competitive Comparison of Inhibrx's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Inhibrx's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibrx's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Inhibrx's 3-Year Revenue Growth Rate falls into.

Inhibrx 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Inhibrx (NAS:INBX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Inhibrx 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Inhibrx's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx (Inhibrx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Inc (NAS:INBX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

Executives

Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Mark Lappe	director, 10 percent owner, officer: Chief Executive Officer	11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Brendan P. Eckelman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jon Faiz Kayyem	director, 10 percent owner	5964 LA PLACE COURT, CARLSBAD CA 92008
Dragsa 50 Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Klaus W. Wagner	officer: Chief Medical Officer	C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kimberly Manhard	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121